The state of Pennsylvania currently has 43 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Recruiting
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Pulmonary Arterial Hypertension
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic Astra/Azure DR MRI IPG.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hypertension, Hypertension, Systolic, Hypertension,Essential
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Recruiting
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2024
Locations: Scott and Christie and Associates /ID# 244574, Cranberry Township, Pennsylvania
Conditions: Open-angle Glaucoma, Ocular Hypertension
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
Recruiting
a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled and/or treatment-resistant hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: AMS Cardiology, Horsham, Pennsylvania +1 locations
Conditions: Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Recruiting
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at ba... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/18/2024
Locations: Research Site, Bethlehem, Pennsylvania +1 locations
Conditions: Uncontrolled Hypertension, Resistant Hypertension
Penn Medicine Healthy Heart
Recruiting
To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
03/18/2024
Locations: Penn Medicine, Philadelphia, Pennsylvania
Conditions: Hypertension, Hyperlipidemias
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/15/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Pulmonary Arterial Hypertension
MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD
Recruiting
The purpose of this study is to evaluate the safety and efficacy of once daily oral inhalation dose of MK-5475 380 µg in participants 40 to 85 years (inclusive) with Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD). The primary hypothesis of the study is MK-5475, a soluble Guanylate Cyclase (sGC) stimulator is superior to placebo in increasing 6 Minute Walking Distance (6MWD) from baseline at Week 24.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
03/15/2024
Locations: Temple University Hospital ( Site 0104), Philadelphia, Pennsylvania
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Recruiting
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/15/2024
Locations: Allegheny General Hospital ( Site 1088), Pittsburgh, Pennsylvania +1 locations
Conditions: Hypertension, Pulmonary
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
Recruiting
IMPAHCT-FUL: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (LTE) Trial is a follow up study to establish the long-term safety of AV-101. The long-term effects of AV-101 on efficacy measures will also be assessed. Subjects who successfully complete the 24-week placebo-controlled parent trial (AV-101-002) will be offered the opportunity to continue into this LTE study. Subjects who enroll in the study will receive one of three active AV-101 doses u... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2024
Locations: UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania
Conditions: Pulmonary Arterial Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +3 locations
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Recruiting
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase 2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance (PVR). The Phase 3 primary endpoint will be the... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/11/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Pulmonary Arterial Hypertension